Back to Search
Start Over
Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).
- Source :
- Endocrine Pathology; Mar2018, Vol. 29 Issue 1, p68-74, 7p
- Publication Year :
- 2018
-
Abstract
- Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor characterized by frequent <italic>RAS</italic> mutations and an absence of the <italic>BRAF</italic> V600E mutation commonly seen in classical papillary thyroid carcinoma (cPTC). The ability to differentiate potential NIFTP/follicular variant of papillary thyroid carcinoma (FVPTC) from cPTC at the time of fine-needle aspiration (FNA) can facilitate conservative management of NIFTP. The aim of the current study was to investigate how molecular testing may add to cytologic assessment in the pre-operative differentiation of potential NIFTP/FVPTC and cPTC. We had previously evaluated cytologists’ ability to prospectively distinguish potential NIFTP/FVPTC from cPTC in a cohort of 56 consecutive FNAs diagnosed as malignant or suspicious for malignancy. We utilized this cohort to perform molecular analysis. Detected molecular abnormalities were stratified into two groups: (1) those supporting malignancy and (2) those supporting a diagnosis of potential NIFTP/FVPTC. The cytologists’ characterization of cases and the detected molecular alterations were correlated with the final histologic diagnoses. Molecular testing was performed in 52 (93%) of the 56 cases. For the 37 cases cytologists favored to be cPTC, 31 (84%) had a molecular result that supported malignancy (28 <italic>BRAF</italic> V600E mutations, 2 <italic>NTRK1</italic> fusions, 1 <italic>AGK</italic>-<italic>BRAF</italic> fusion). For the 8 cases that were favored to be NIFTP/FVPTC by cytologists, 7 (88%) had a molecular result that supported conservative management (1 <italic>NRAS</italic> mutation, 6 wild-type result). Seven cases were designated as cytomorphologically indeterminate for NIFTP/FVPTC or cPTC, of which 6 (86%) had a molecular result that would have aided in the pre-operative assessment of potential NIFTP/FVPTC or cPTC/malignancy. These included 3 <italic>BRAF</italic> V600E mutations in nodules that were cPTC on resection, an <italic>HRAS</italic> mutation, and a wild-type result in the 2 nodules that were NIFTP, and a <italic>TERT</italic> promoter mutation along with an <italic>NRAS</italic> mutation in a poorly differentiated thyroid carcinoma. For nodules with an FNA diagnosis of suspicious for malignancy or malignant, cytologists can differentiate most cases of potential NIFTP/FVPTC from cPTC. However, molecular testing may be valuable for a subset of cases, especially those that are indeterminate for potential NIFTP/FVPTC versus cPTC based on cytologic features alone. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10463976
- Volume :
- 29
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Endocrine Pathology
- Publication Type :
- Academic Journal
- Accession number :
- 128186190
- Full Text :
- https://doi.org/10.1007/s12022-018-9515-x